Adagio Therapeutics, Inc. Announces 2022 Annual Meeting of Stockholders

Rhea-AI Summary

Adagio Therapeutics (NASDAQ: ADGI) has announced its 2022 Annual Meeting of Stockholders, scheduled for May 26, 2022, at 8:30 a.m. Eastern Time, to be held virtually. Further details will be provided in the upcoming Proxy Statement with the SEC. Adagio focuses on developing antibody-based treatments for infectious diseases, leveraging advanced engineering for improved efficacy and manufacturability. Their investigational monoclonal antibody, ADG20, is designed to offer broad protection against COVID-19, though it is not yet approved for use, and its safety and efficacy remain unestablished.

Positive

• Adagio's focus on antibody-based solutions addresses high-demand infectious diseases like COVID-19.
• The company has secured manufacturing capacity for ADG20, suggesting readiness for effective clinical trials.

Negative

• ADG20 is still investigational and has not yet been approved for use, which poses a risk for the company's market potential.
• The safety and efficacy of ADG20 have not been established, creating uncertainty for investors.

WALTHAM, Mass., March 18, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (NASDAQ: ADGI) today announced that it will hold its 2022 Annual Meeting of Stockholders virtually at 8:30 a.m. Eastern Time on May 26, 2022. Additional information regarding the Company’s 2022 Annual Meeting of Stockholders will be disclosed in the Company’s Proxy Statement to be filed with the Securities and Exchange Commission.

About Adagio Therapeutics

Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, including COVID-19 and influenza. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with the potential for a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple non-competing, broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers to support clinical trials and initial launch quantities, ensuring the potential for broad accessibility to people around the world. ADG20 is an investigational monoclonal antibody that is not approved for use in any country. The safety and efficacy of ADG20 have not been established. For more information, please visit www.adagiotx.com.

Contacts:

Media Contact:
Dan Budwick, 1AB
dan@1abmedia.com

Investor Contact:
Monique Allaire, THRUST Strategic Communications
monique@thrustsc.com

FAQ

What is the date and time of Adagio Therapeutics' 2022 Annual Meeting of Stockholders?

The 2022 Annual Meeting of Stockholders for Adagio Therapeutics is scheduled for May 26, 2022, at 8:30 a.m. Eastern Time.

Where can I find more information about Adagio Therapeutics' 2022 Annual Meeting?

Additional information regarding the Annual Meeting will be disclosed in the Company's Proxy Statement to be filed with the SEC.

What is the status of ADG20, the investigational monoclonal antibody from Adagio?

ADG20 is still in the investigational stage and has not been approved for use in any country.

What infectious diseases does Adagio Therapeutics focus on?

Adagio Therapeutics focuses on infectious diseases with pandemic potential, including COVID-19 and influenza.